Arvinas Inc. (ARVN)
NASDAQ (NGS) NASDAQ (NGS) Primary Summary
Arvinas Sharpens Pipeline Focus After First PROTAC Approval, Eyes Key Trial Data
Arvinas NASDAQ: ARVN management outlined a more selective development strategy at a Jefferies-hosted investor discussion, emphasizing internal investment in neurological and oncology programs where the company believes it can create differentiated therapies, while seeking partners for assets that may require broader development resources.
Arvinas, Inc. (ARVN) Q1 2026 Earnings Call Transcript
Arvinas, Inc. (ARVN) Q1 2026 Earnings Call Transcript
Arvinas Q1 Earnings Call Highlights
Arvinas NASDAQ: ARVN said its first quarter was marked by the FDA approval of VEPPANU, a new licensing agreement with Rigel Pharmaceuticals and continued progress across a clinical-stage pipeline focused on targeted protein degradation.
Arvinas Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Anthony Scaramucci SkyBridge Capital II LLC | 1.98M | $18.58M | $14.02M | -$4.55M | -24.51% |
 Point72 Asset Management LP Point72 Asset Management LP | 229,807 | $2.73M | $1.63M | -$1.1M | -40.22% |
| JC Joseph Castro Nuveen LLC | 406,340 | $3.8M | $2.88M | -$915,093.9 | -24.11% |
| BB Brian Baylis Bell Investment Advisors Inc. | 11 | $292.82 | $77.99 | -$214.83 | -73.37% |
| JG Jennifer Grunberg Allspring Global Investments Holdings LLC | 51,923 | $414,092 | $368,134.07 | -$45,957.93 | -11.1% |
Arvinas Inc. (ARVN) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Arvinas Inc. ever had a stock split?
Arvinas Inc. Profile
| Biotechnology Industry | Healthcare Sector | Randy Teel CEO | NASDAQ (NGS) Exchange | 04335A105 CUSIP |
| US Country | 430 Employees | - Last Dividend | - Last Split | 27 Sep 2018 IPO Date |
Overview
Arvinas, Inc. is a pioneering clinical-stage biotechnology firm focused on creating innovative therapies aimed at the degradation of disease-causing proteins. By designing proteolysis targeting chimeras (PROTAC) targeted protein degraders, Arvinas takes advantage of the body's own protein disposal mechanism to eliminate harmful proteins. Since its inception in 2013 and based in New Haven, Connecticut, Arvinas has established significant collaborations with industry leaders such as Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. These partnerships aim to bolster the development and potential commercialization of its groundbreaking therapies.
Products and Services
- Bavdegalutamide and ARV-766
- ARV-471
These are investigational, orally bioavailable PROTAC protein degraders designed specifically for the treatment of men with metastatic castration-resistant prostate cancer. Currently, these products are under Phase 1/2 clinical trials, demonstrating Arvinas, Inc.'s commitment to addressing this challenging health issue through innovative therapeutic solutions.
ARV-471 represents a pioneering approach as an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader. It's crafted for patients with locally advanced or metastatic estrogen receptor-positive/human epidermal growth factor receptor 2-negative breast cancer. With ARV-471 advancing to Phase 3 clinical trials, it underscores the company's focus on leveraging its proprietary technology to combat severe and widespread forms of cancer, offering hope for more effective treatments.
